JP2019506143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506143A5 JP2019506143A5 JP2018530845A JP2018530845A JP2019506143A5 JP 2019506143 A5 JP2019506143 A5 JP 2019506143A5 JP 2018530845 A JP2018530845 A JP 2018530845A JP 2018530845 A JP2018530845 A JP 2018530845A JP 2019506143 A5 JP2019506143 A5 JP 2019506143A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- polypeptide region
- region
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 544
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 540
- 229920001184 polypeptide Polymers 0.000 claims description 536
- 210000004027 cell Anatomy 0.000 claims description 405
- 102000039446 nucleic acids Human genes 0.000 claims description 195
- 108020004707 nucleic acids Proteins 0.000 claims description 195
- 150000007523 nucleic acids Chemical class 0.000 claims description 195
- 238000000034 method Methods 0.000 claims description 183
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 122
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 122
- 108091033319 polynucleotide Proteins 0.000 claims description 120
- 102000040430 polynucleotide Human genes 0.000 claims description 120
- 239000002157 polynucleotide Substances 0.000 claims description 120
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 112
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 103
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 103
- 239000000427 antigen Substances 0.000 claims description 77
- 108091007433 antigens Proteins 0.000 claims description 77
- 102000036639 antigens Human genes 0.000 claims description 77
- 230000000139 costimulatory effect Effects 0.000 claims description 70
- 101150013553 CD40 gene Proteins 0.000 claims description 54
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 54
- 229960002930 sirolimus Drugs 0.000 claims description 51
- 230000001086 cytosolic effect Effects 0.000 claims description 33
- 102000004039 Caspase-9 Human genes 0.000 claims description 32
- 108090000566 Caspase-9 Proteins 0.000 claims description 32
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 102000002164 CARD domains Human genes 0.000 claims description 21
- 108050009503 CARD domains Proteins 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 102000011727 Caspases Human genes 0.000 claims description 19
- 108010076667 Caspases Proteins 0.000 claims description 19
- -1 p-dimethoxyphenyl Chemical group 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 230000003213 activating effect Effects 0.000 claims description 13
- 210000000822 natural killer cell Anatomy 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 11
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 9
- 101150029707 ERBB2 gene Proteins 0.000 claims description 9
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 9
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 9
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 9
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 9
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 9
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 9
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 9
- 102000003735 Mesothelin Human genes 0.000 claims description 9
- 108090000015 Mesothelin Proteins 0.000 claims description 9
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 9
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 9
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 claims description 8
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 claims description 8
- 102000009438 IgE Receptors Human genes 0.000 claims description 8
- 108010073816 IgE Receptors Proteins 0.000 claims description 8
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 8
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 8
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 8
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 5
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 5
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 108060006580 PRAME Proteins 0.000 claims description 5
- 102000036673 PRAME Human genes 0.000 claims description 5
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 4
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 claims description 4
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 4
- 108090000397 Caspase 3 Proteins 0.000 claims description 4
- 102000004018 Caspase 6 Human genes 0.000 claims description 4
- 108090000425 Caspase 6 Proteins 0.000 claims description 4
- 108090000567 Caspase 7 Proteins 0.000 claims description 4
- 102100035904 Caspase-1 Human genes 0.000 claims description 4
- 108090000426 Caspase-1 Proteins 0.000 claims description 4
- 102000004068 Caspase-10 Human genes 0.000 claims description 4
- 108090000572 Caspase-10 Proteins 0.000 claims description 4
- 102000004066 Caspase-12 Human genes 0.000 claims description 4
- 108090000570 Caspase-12 Proteins 0.000 claims description 4
- 102000004958 Caspase-14 Human genes 0.000 claims description 4
- 108090001132 Caspase-14 Proteins 0.000 claims description 4
- 102000004046 Caspase-2 Human genes 0.000 claims description 4
- 108090000552 Caspase-2 Proteins 0.000 claims description 4
- 102100029855 Caspase-3 Human genes 0.000 claims description 4
- 102100025597 Caspase-4 Human genes 0.000 claims description 4
- 101710090338 Caspase-4 Proteins 0.000 claims description 4
- 102100038916 Caspase-5 Human genes 0.000 claims description 4
- 101710090333 Caspase-5 Proteins 0.000 claims description 4
- 102100038902 Caspase-7 Human genes 0.000 claims description 4
- 108090000538 Caspase-8 Proteins 0.000 claims description 4
- 102100026693 FAS-associated death domain protein Human genes 0.000 claims description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 4
- 101000924629 Homo sapiens Apoptotic protease-activating factor 1 Proteins 0.000 claims description 4
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims description 4
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims description 4
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims description 4
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims description 4
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 claims description 4
- 102000055102 bcl-2-Associated X Human genes 0.000 claims description 4
- 108010018550 caspase 13 Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 4
- 230000000527 lymphocytic effect Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 4
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000004986 primary T-cell Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims 9
- 102100026548 Caspase-8 Human genes 0.000 claims 1
- 239000003446 ligand Substances 0.000 description 179
- 239000000203 mixture Substances 0.000 description 40
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 34
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 241000700605 Viruses Species 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 7
- 206010010099 Combined immunodeficiency Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 4
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000014752 hemophagocytic syndrome Diseases 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102100033051 40S ribosomal protein S19 Human genes 0.000 description 2
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 201000007155 CD40 ligand deficiency Diseases 0.000 description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010062759 Congenital dyskeratosis Diseases 0.000 description 2
- 208000025212 Constitutional neutropenia Diseases 0.000 description 2
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 201000004939 Fanconi anemia Diseases 0.000 description 2
- 208000000259 GATA2 Deficiency Diseases 0.000 description 2
- 208000022140 GATA2 deficiency with susceptibility to MDS/AML Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 2
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 2
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 208000026378 Polyglandular endocrine disease Diseases 0.000 description 2
- 208000031951 Primary immunodeficiency Diseases 0.000 description 2
- 208000010346 Sphingolipidoses Diseases 0.000 description 2
- 201000001307 Sphingolipidosis Diseases 0.000 description 2
- 201000001322 T cell deficiency Diseases 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 208000015322 bone marrow disease Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000009356 dyskeratosis congenita Diseases 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 230000003258 hemophagocytic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000014165 immunodeficiency 21 Diseases 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021200645A JP2022031906A (ja) | 2015-12-14 | 2021-12-10 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2024105063A JP2024120106A (ja) | 2015-12-14 | 2024-06-28 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2024105062A JP2024120105A (ja) | 2015-12-14 | 2024-06-28 | 治療用細胞の活性化及び排除のための二重コントロール |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267277P | 2015-12-14 | 2015-12-14 | |
| US62/267,277 | 2015-12-14 | ||
| PCT/US2016/066371 WO2017106185A2 (en) | 2015-12-14 | 2016-12-13 | Dual controls for therapeutic cell activation or elimination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200645A Division JP2022031906A (ja) | 2015-12-14 | 2021-12-10 | 治療用細胞の活性化及び排除のための二重コントロール |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019506143A JP2019506143A (ja) | 2019-03-07 |
| JP2019506143A5 true JP2019506143A5 (enExample) | 2020-01-16 |
Family
ID=57799788
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530845A Withdrawn JP2019506143A (ja) | 2015-12-14 | 2016-12-13 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2021200645A Withdrawn JP2022031906A (ja) | 2015-12-14 | 2021-12-10 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2024105062A Pending JP2024120105A (ja) | 2015-12-14 | 2024-06-28 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2024105063A Pending JP2024120106A (ja) | 2015-12-14 | 2024-06-28 | 治療用細胞の活性化及び排除のための二重コントロール |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200645A Withdrawn JP2022031906A (ja) | 2015-12-14 | 2021-12-10 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2024105062A Pending JP2024120105A (ja) | 2015-12-14 | 2024-06-28 | 治療用細胞の活性化及び排除のための二重コントロール |
| JP2024105063A Pending JP2024120106A (ja) | 2015-12-14 | 2024-06-28 | 治療用細胞の活性化及び排除のための二重コントロール |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170166877A1 (enExample) |
| EP (1) | EP3390434A2 (enExample) |
| JP (4) | JP2019506143A (enExample) |
| KR (1) | KR20180087423A (enExample) |
| CN (2) | CN108779163A (enExample) |
| AU (1) | AU2016370470B2 (enExample) |
| CA (1) | CA3007473A1 (enExample) |
| SG (1) | SG11201804694SA (enExample) |
| WO (1) | WO2017106185A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| JP6868554B2 (ja) | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| CA2978171A1 (en) * | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN110494543A (zh) | 2016-10-19 | 2019-11-22 | 弗洛设计声能学公司 | 通过声学的亲和细胞提取 |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US20210147507A1 (en) | 2017-05-09 | 2021-05-20 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| EP3720479A2 (en) | 2017-12-08 | 2020-10-14 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining car-t cell efficacy |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3728189A1 (en) | 2017-12-20 | 2020-10-28 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| CA3083779A1 (en) | 2017-12-22 | 2019-06-27 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| JP7480064B2 (ja) | 2018-02-27 | 2024-05-09 | グリットストーン バイオ インコーポレイテッド | パンアレルモデルによる新生抗原の特定方法 |
| CN111954715A (zh) | 2018-03-29 | 2020-11-17 | 菲特治疗公司 | 工程改造的免疫效应细胞和其用途 |
| CA3091490A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| US12448426B2 (en) | 2018-05-17 | 2025-10-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains |
| CN111373571A (zh) | 2018-07-26 | 2020-07-03 | 株式会社Lg化学 | 隔板和包括该隔板的电化学装置 |
| KR20210099601A (ko) | 2018-12-02 | 2021-08-12 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 iPSC 유래 효과기 세포를 사용한 면역요법 |
| CN113423822A (zh) * | 2018-12-13 | 2021-09-21 | 贝里坤制药股份有限公司 | Psca car-t细胞 |
| EP3920888A4 (en) * | 2019-02-04 | 2023-11-01 | Oisin Biotechnologies, Inc. | FUSOGENIC LIPID NANOPARTICLES FOR TARGET CELL-SPECIFIC PRODUCTION OF RAPAMYCIN-INDUCIBLE THERAPEUTIC PROTEINS |
| WO2020219504A1 (en) * | 2019-04-23 | 2020-10-29 | The Regents Of The University Of California | Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto |
| CN110079504A (zh) * | 2019-05-06 | 2019-08-02 | 山东大学第二医院 | 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法 |
| CN114423498A (zh) * | 2019-08-12 | 2022-04-29 | 贝里坤制药股份有限公司 | 免疫细胞的改进制剂 |
| CN110592014A (zh) * | 2019-08-14 | 2019-12-20 | 广东美赛尔细胞生物科技有限公司 | 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法 |
| CN112430578A (zh) * | 2019-08-26 | 2021-03-02 | 深圳宾德生物技术有限公司 | 携带安全开关并靶向Her2的嵌合抗原受体T细胞及其制备方法和应用 |
| US20220306715A1 (en) * | 2019-08-30 | 2022-09-29 | Shattuck Labs, Inc. | Chimeric proteins in autoimmunity |
| US20230104317A1 (en) * | 2020-01-31 | 2023-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods to Identify Genetic Silencers and Applications Thereof |
| WO2021231806A1 (en) * | 2020-05-13 | 2021-11-18 | Rapa Therapeutics, Llc | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same |
| WO2021257574A1 (en) * | 2020-06-15 | 2021-12-23 | Kiromic Biopharma Inc. | Tri-switch technology for multi-dimensional control of cell therapy |
| US12275955B2 (en) | 2020-06-19 | 2025-04-15 | Fate Therapeutics, Inc. | Combining iPSC derived effector cell types for immunotherapy use |
| CN112575035B (zh) * | 2020-12-09 | 2022-11-29 | 贵州医科大学 | 一种诱导细胞凋亡的载体系统 |
| AU2023249802A1 (en) | 2022-04-08 | 2024-10-24 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| CN118871471A (zh) | 2022-04-08 | 2024-10-29 | 菲特治疗公司 | 用于肿瘤靶向的嵌合抗原受体 |
| CN119654336A (zh) * | 2022-05-16 | 2025-03-18 | 儿童医疗中心有限公司 | 治疗心脏病的组合物和方法 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| WO2025054345A1 (en) * | 2023-09-05 | 2025-03-13 | Remedium Bio, Inc. | Genetic elements for adjustment of expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| AU755784B2 (en) * | 1998-01-15 | 2002-12-19 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using multimeric chimeric proteins |
| KR20150131218A (ko) * | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| CA2912172A1 (en) * | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| EP3925618A1 (en) * | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| CN106132423B (zh) * | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
-
2016
- 2016-12-13 EP EP16826509.8A patent/EP3390434A2/en active Pending
- 2016-12-13 JP JP2018530845A patent/JP2019506143A/ja not_active Withdrawn
- 2016-12-13 KR KR1020187020145A patent/KR20180087423A/ko not_active Ceased
- 2016-12-13 CA CA3007473A patent/CA3007473A1/en active Pending
- 2016-12-13 CN CN201680081930.1A patent/CN108779163A/zh active Pending
- 2016-12-13 SG SG11201804694SA patent/SG11201804694SA/en unknown
- 2016-12-13 US US15/377,776 patent/US20170166877A1/en not_active Abandoned
- 2016-12-13 AU AU2016370470A patent/AU2016370470B2/en not_active Ceased
- 2016-12-13 CN CN202310839876.4A patent/CN117402829A/zh active Pending
- 2016-12-13 WO PCT/US2016/066371 patent/WO2017106185A2/en not_active Ceased
-
2021
- 2021-03-31 US US17/219,116 patent/US20230065562A1/en not_active Abandoned
- 2021-12-10 JP JP2021200645A patent/JP2022031906A/ja not_active Withdrawn
-
2023
- 2023-09-21 US US18/471,761 patent/US20240368574A1/en active Pending
-
2024
- 2024-06-28 JP JP2024105062A patent/JP2024120105A/ja active Pending
- 2024-06-28 JP JP2024105063A patent/JP2024120106A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506143A5 (enExample) | ||
| JP6931598B2 (ja) | Ｃｄ４＋ｔ細胞応答を向上するための修飾されたエピトープ | |
| EP1434596B1 (en) | Enhancement of immune responses by agonist 4-1bb-antibodies | |
| US20220267732A1 (en) | Dux4 expressing cells and uses thereof | |
| KR101902029B1 (ko) | 감염성 질환, 자가면역 질환, 동종인자에 대한 면역 반응, 알레르기 질환, 종양, 이식편 거부 및 유전자 요법 또는 유전자 백신접종을 위해 사용되는 바이러스 벡터에 대한 면역 반응의 예방 및/또는 치료에 사용하기 위한 면역원성 펩티드 | |
| JP2018501786A5 (enExample) | ||
| JP7320947B2 (ja) | 新規な免疫原性ＣＤ１ｄ結合ペプチド | |
| US20200165302A1 (en) | Modified vsv-g and vaccines thereof | |
| CN113748127A (zh) | 使用cd8改造的t细胞疗法治疗癌症的组合物和方法 | |
| US12103956B2 (en) | Suicide module compositions and methods | |
| JP2018500019A5 (enExample) | ||
| JP2016521709A5 (enExample) | ||
| CN113366102A (zh) | 包含hla-e和hla-g分子的人工抗原呈递细胞和使用方法 | |
| JP2022513021A (ja) | 向上した酸化還元酵素モチーフを有する免疫原性ペプチド | |
| JPWO2020138371A1 (ja) | 改変ｔｃｒ及びその製造方法 | |
| CN1871025B (zh) | 基于印记位点调节物兄弟(boris)的预防性癌症疫苗 | |
| CN113383069B (zh) | 使用转化的t细胞培养脐带血来源的自然杀伤细胞的方法 | |
| US10781423B2 (en) | Method for producing B cell population | |
| JP2025515603A (ja) | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 | |
| JPWO2019236577A5 (enExample) | ||
| US12359169B2 (en) | Universal CAR-T cell and preparation method and use thereof | |
| CN101378783A (zh) | 用于扩增t调节细胞的方法和组合物 | |
| JPWO2020085480A1 (ja) | 高効率な遺伝子改変細胞の作製方法 | |
| RU2023106937A (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| HK40050291B (en) | Suicide module compositions and methods |